A carregar...

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

BACKGROUND: The CD34(+)CD38(-) subset of AML cells is enriched for resistance to current chemotherapeutic agents and considered to contribute to disease progression and relapse in Acute Myeloid Leukaemia (AML) patients following initial treatment. METHODS: Chemosensitivity in phenotypically defined...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jawad, Mays, Yu, Ning, Seedhouse, Claire, Tandon, Karuna, Russell, Nigel H, Pallis, Monica
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3488582/
https://ncbi.nlm.nih.gov/pubmed/23013471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!